FOR IMMEDIATE RELEASE
Contact:
David W. Moskowitz MD
CEO, GenoMed
Tel. 314.983.9933
dwmoskowitz@genomed.com
Skype ID: dwmoskowitz
ST. LOUIS—March 9, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that it has already given 5,000 free medical consultations over the Internet. Most have been for Parkinson’s disease, chronic fatigue syndrome, emphysema, diabetes, cancer, and West Nile virus encephalitis.
Depending on the situation, GenoMed may have more to offer. For example, GenoMed has already published superior clinical outcomes for diabetes, high blood pressure, and emphysema. For these diseases, GenoMed can recommend its Clinical Outcomes Improvement Program, or COIP®, which costs $75/month, confident that it can provide better patient outcomes than anybody else in the world.
For many additional diseases, GenoMed can offer a free clinical trial. The trial is designed to first do no harm. If the trial fails in enough people, it’s no longer offered. For example, GenoMed’s approach, using a single drug, was successful for acute alopecia areata, but not for chronic alopecia universalis. The trial for acute alopecia areata is still open, but the original trial for alopecia universalis was closed. Now GenoMed is offering a new trial for alopecia universalis, featuring two drugs, not just one.
Said Dr. Moskowitz, GenoMed’s CEO and Chief Medical Officer, “Cardiovascular disease and cancer are the two main killers. We know that we can slow down cardiovascular disease, the #1 killer. Plenty of Internet sites provide general medical information, but we’re the only one I know of that will suggest a specific treatment plan that’s supported by papers published in the medical literature.”
“Patients, I’m sure, appreciate,” continued Dr. Moskowitz, “that most diseases still haven’t been solved, or the current ‘solution’ is too expensive or toxic. MS (multiple sclerosis) is a perfect example. We think a simple pill may work at least as well, with fewer side effects, than the expensive shots currently offered. For patients without health insurance, our approach is the only one that makes sense, even though it’s experimental.”
Dr. Moskowitz ended by saying, “Medicine, more than any other science, advances by trial-and-error. Genomics may have finally given us the key to defeating common diseases, since it identifies steps in the disease pathway. We’re sure of our results with cardiovascular disease. Now we’re extending our reach to additional diseases. By helping each other, GenoMed, working with patients around the world, can defeat these diseases.”
About GenoMed
GenoMed (www.genomed.com) published how to prevent 90% of kidney failure, and how to retard the progression of emphysema (COPD) in 2002. The company’s “recipes” are the subject of pending patents in the US. Two patents have been awarded: one for treating acute kidney failure without dialysis, and a second for hastening lung maturation in premature infants. Anyone wishing to help sponsor GenoMed’s free medical advice is invited to contact Dr. Moskowitz (please see contact info above).
Safe Harbor Statement
This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.’s (the Company’s) finances and treatments. The words or phrases “ought to,” “should,” “could,” “may,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors, and the possibility of our not being able to field all the calls and emails we receive. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.